SwarnsaritaJewel (526365)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Price-to-book of 0.46 provides a significant discount to stated book value of ₹63.48
• P/E of 6.51 is low on a trailing basis, offering apparent valuation support
• Latest quarter reported ₹218 crore sales with a positive, albeit thin, net profit of ₹2 crore
• Trading near 52-week low of ₹28.63 suggests limited speculative froth

Concerns

• Profit growth declined 27.07% while sales growth was negative at -0.37%, indicating deterioration
• ROE of 7.09% and ROCE of 7.40% are weak, barely above risk-free returns
• Piotroski F-Score of 3/9 signals poor financial health and rising red flags
• No dividend and no promoter holding disclosure reduce transparency and shareholder return

AI Analysis

Looking at SwarnsaritaJewel, I see a classic value trap warning. The stock trades at ₹29.19 with a book value of ₹63.48, a P/B of 0.46. That means I am paying less than 50 paise for every rupee of stated net assets. On the surface, that seems like a deep margin of safety. But as Graham taught, a bargain must also have a decent earning power. Here, ROE is just 7.09% and ROCE is 7.40% — these returns are not much better than a fixed deposit, and they are shrinking. Profit growth is down 27.07%, and sales are flat at -0.37%. The latest quarter shows ₹218 crore of sales but only ₹2 crore of net profit, which translates to a razor-thin margin of under 1%. Jewellery is a competitive, low-moat business, and the Piotroski F-Score of 3/9 is a red flag. It tells me the financial condition has deteriorated. There is no dividend, so the shareholder must rely solely on price appreciation or asset realisation. The 52-week range is ₹28.63 to ₹40.50, and the price sits near the low, so the market is not rewarding this stock. In India, gems and jewellery also face regulatory and demand cyclicality. I cannot invent promoter data, and the lack of disclosure itself is a concern. While the low P/B provides a statistical cushion, the weak returns and negative momentum make this more of an asset play than a quality compounder. I would demand a higher margin of safety, and even then, only a patient, contrarian investor should consider it.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer